Research Reports

Key takeaways

Dr. Laura Sepp-Lorenzino appointed to Lexeo Therapeutics board on April 28, 2026, term expires at 2028 Annual Meeting.

Appointed to Science and Technology Committee.

Extensive experience: Principal GNMmeds LLC since 2025; prior CSO Intellia Therapeutics, VP Vertex Pharmaceuticals, roles at Alnylam and Merck.

Initial compensation: $40,000 annual cash, 50,000-share stock option; annual 25,000-share option from 2027.

No arrangements or family relationships tied to appointment.

Full analysis

Dr. Sepp-Lorenzino brings deep expertise in genomic medicine, nucleic acid therapies, and oncology from leadership roles at Intellia, Vertex, Alnylam, and Merck, plus current board seats at Taysha Gene Therapies and others. Her appointment to the board and Science and Technology Committee strengthens Lexeo's strategic oversight in biotechnology R&D. Compensation aligns with the Non-Employee Director Policy, providing market-standard cash and equity incentives without immediate annual grant due to timing near the 2026 stockholder meeting. No related-party conflicts disclosed.

LXEO · Lexeo Therapeutics, Inc. Common Stock

Summary

Key takeaways

Full analysis